# PeptideScanner evidence objects: FOXO4-DRI

Every published version of the records placed with FOXO4-DRI, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/foxo4-dri.json. Selected public evidence only; not medical advice.

- Objects: 2
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="pubmed-pmid-33996787-foxo4-dri-v1"></a>

## Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes.

> PubMed lists PMID 33996787 in Frontiers in bioengineering and biotechnology as Journal Article, with publication-date metadata of 2021-04-29 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33996787-foxo4-dri:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-02-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33996787-foxo4-dri/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/foxo4-dri.json#pubmed-pmid-33996787-foxo4-dri-v1
- Content SHA-256: `ba11444bb991bb8ffe956bce784b67058a63a37804aea552c3d077079ace4a15`

### Claims and source pins

#### Headline

Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. ([`pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a`](#source-pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a))

#### Summary

PubMed lists PMID 33996787 in Frontiers in bioengineering and biotechnology as Journal Article, with publication-date metadata of 2021-04-29 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a`](#source-pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a))

#### Paragraph 1

PubMed lists PMID 33996787 in Frontiers in bioengineering and biotechnology as Journal Article, with publication-date metadata of 2021-04-29 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a`](#source-pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a`](#source-pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a))

### Sources

<a id="source-pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a"></a>
- **Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. · retained source version 1:2022-02-01:current:d5f8ee6e316af95181837000f97a1a7561b9724dec5766f7efda10dffd1f695c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33996787/) (`pubmed-observation-pmid-33996787-2022-02-01-d5f8ee6e316a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/foxo4-dri.json#pubmed-pmid-33996787-foxo4-dri-v1 SHA-256: ba11444bb991bb8ffe956bce784b67058a63a37804aea552c3d077079ace4a15.

---

<a id="pubmed-pmid-40593617-foxo4-dri-v1"></a>

## The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.

> PubMed lists PMID 40593617 in Nature communications as Journal Article, with publication-date metadata of 2025-07-01 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40593617-foxo4-dri:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40593617-foxo4-dri/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/foxo4-dri.json#pubmed-pmid-40593617-foxo4-dri-v1
- Content SHA-256: `2f16b23ec2352f51bc4f8c1816fde1d5e3ae74eaaee1811bb3a895e37cb3fd5a`

### Claims and source pins

#### Headline

The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. ([`pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e`](#source-pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e))

#### Summary

PubMed lists PMID 40593617 in Nature communications as Journal Article, with publication-date metadata of 2025-07-01 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e`](#source-pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e))

#### Paragraph 1

PubMed lists PMID 40593617 in Nature communications as Journal Article, with publication-date metadata of 2025-07-01 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e`](#source-pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e`](#source-pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e))

### Sources

<a id="source-pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e"></a>
- **The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. · retained source version 1:2025-07-04:current:abbaa47a024e3ff12fee4ca52627a3f679852ccfd5a2f79f0af0567b8a2ab3ef** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40593617/) (`pubmed-observation-pmid-40593617-2025-07-04-abbaa47a024e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/foxo4-dri.json#pubmed-pmid-40593617-foxo4-dri-v1 SHA-256: 2f16b23ec2352f51bc4f8c1816fde1d5e3ae74eaaee1811bb3a895e37cb3fd5a.

